Location:

Local - Houston Metro

Add to Favorites | Subscribe | Share

Filters:

  • (Press "esc" to clear)

Medicine

Channels:

anti-NMDAR encephalitis, Encephalitis, anti-N-methyl D-aspartate receptor encephalitis, Comatose, Respirator, Pulmonary, Psychiatric, Limbic

Brain Illness that Crippled Teen Isn’t Defining his Future

KGuntupalli-clinical-s.jpg

Comatose and unable to talk for nearly a year and half, a 24-year-old is again living a normal life. Harris Health System's medical team identified his condition as anti-N-methyl D-aspartate receptor encephalitis (anti-NMDA), a rare, and sometimes, difficult disease to identify and properly treat.

Medicine

Channels:

HPV, Vaccination, Vaccine, men

UTHealth Study Finds That Male Virgins Can Still Acquire HPV

Alan-Nyitray-web.jpg

Men who have never engaged in sexual intercourse are still at risk for acquiring HPV, according to a study published recently in the Journal of Infectious Diseases by researchers at The University of Texas Health Science Center at Houston (UTHealth) School of Public Health.

Medicine

Channels:

Schizophrenia, bipolar, Bipolar Disorder, Bipolar Teens, Immune System, immune system disorder, anti-NMDAR encephalitis, Brain on Fire, immunotheraphy, NMDA, Nmda Receptor, hearing voices, paranoia, Schizophrenia research, Schizophrenia Treatment, bipolar disorders, bipolar research, Homeless, homeless adults, Homeless children

Treatable Condition Could Be Mistaken for Schizophrenia or Bipolar Disorder

Researchers at Houston Methodist believe that a significant number of people diagnosed with schizophrenia or bipolar disorder may actually have a treatable immune system condition. A new research study could have a significant impact on the millions diagnosed with schizophrenia or bipolar disorder, including many homeless.

Medicine

Channels:

McGovern Medical School at The University of Texas Health Science Center at Houston (UTHealth), Bipolar Disorder, epigenetic age, accelerated aging, Translational Psychiatry, Gabriel Fries, Joao de Quevedo

UTHealth Researchers Link Epigenetic Aging to Bipolar Disorder

Friesinlab.jpg

Bipolar disorder may involve accelerated epigenetic aging, which could explain why persons with the disorder are more likely to have – and die from – age-related diseases, according to researchers from McGovern Medical School at UTHealth Houston.

Medicine

Channels:

MD Anderson Cancer Center, AML acute myeloid leukemia, American Society Of Hematology

AML Study Reports High Response Rates with Combination Targeted Therapy

Andreef2.jpg

Initial findings from a multi-national open-label phase Ib study of inhibitory drug therapy for relapsed or refractory acute myeloid leukemia (AML) have demonstrated a complete response in up to 50 percent patients say researchers at The University of Texas MD Anderson Cancer Center .

Medicine

Channels:

Phase 2 CAR-T Study Reports Significant Remission Rates at 15-Month Follow Up

Neelapu.jpg

A study involving the recently approved CD19-targeting chimeric antigen receptor (CAR) T cell therapy shows that 42 percent of patients with aggressive large B-cell lymphoma remained in remission at 15 months following treatment with axi-cel (marketed as Yescarta™).

Medicine

Channels:

MD Anderson Cancer Center, Breast Cancer, San Antonio Breast Cancer Symposium, PARP inhibitor, Brca Gene

PARP Inhibitor Improves Progression-Free Survival in Patients with Advanced Breast Cancers and BRCA Mutations

150401_LItton_J.jpg

In a randomized, Phase III trial led by researchers at The University of Texas MD Anderson Cancer Center, the PARP inhibitor talazoparib extended progression-free survival (PFS) and improved quality-of-life measures over available chemotherapies for patients with metastatic HER2-negative breast cancer and mutations in the BRCA1/2 genes.

Medicine

Channels:

MD Anderson Cancer Center, MONALEESA-7, San Antonio Breast Cancer Symposium, Breast Cancer

Ribociclib Extends Progression-Free Survival in Pre-Menopausal Patients with Metastatic Hormone Receptor-Positive Breast Cancer

210220_Tripathy_D.jpg

The addition of ribociclib, an inhibitor of the cell cycle, to standard hormone therapy significantly improved progression-free survival (PFS) in pre-menopausal patients with advanced hormone receptor-positive (HR+) breast cancer, according to results of the MONALEESA-7 Phase III clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

Medicine

Channels:

MD Anderson Cancer Center, Brain Tumors

Novel Regulation of Gene Expression in Brain Tumors Identified

Lu_Zhimen6.jpg

Study results revealed previously unknown interplay between two key enzymes and a novel understanding of how brain cancer tumors form and spread, according to researchers at The University of Texas MD Anderson Cancer Center.

Medicine

Channels:

ASH annual meeting, MD Anderson Cancer Center, Blood Cancers

MD Anderson to Present Key Drug Study Findings for Multiple Blood Cancers at ASH Annual Meeting

Researchers at The University of Texas MD Anderson Cancer Center will present their latest findings involving drug treatments for blood cancers at the American Society of Hematology’s (ASH) Annual Meeting & Exposition Dec. 8-12 in Atlanta.







Chat now!